CIM
VRTX icon

Chiron Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Chiron Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,496
Closed -$5.9M – 129
2023
Q4 		$5.9M Buy
14,496
+13,841
+2,113% +$5.11M 2.25% 22
2023
Q3 		$228K Sell
655
-21,714
-97% -$7.59M 0.1% 48
2023
Q2 		$7.87M Buy
22,369
+12,859
+135% +$4.33M 2.21% 21
2023
Q1 		$3M Buy
9,510
+9,392
+7,959% +$2.82M 0.54% 36
2022
Q4 		$34.1K Sell
118
-69,156
-100% -$21.1M 0.01% 126
2022
Q3 		$20.1M Sell
69,274
-3,972
-5% -$1.14M 4.04% 7
2022
Q2 		$20.6M Sell
73,246
-13,875
-16% -$3.71M 3.46% 9
2022
Q1 		$22.7M Buy
+87,121
New +$20.7M 2.61% 17
2020
Q4 		– Sell
-33,274
Closed -$9.05M – 118
2020
Q3 		$9.05M Buy
33,274
+16,603
+100% +$4.58M 1.68% 33
2020
Q2 		$4.84M Buy
+16,671
New +$4.52M 1.04% 37
2019
Q2 		– Sell
-136,907
Closed -$25.2M – 59
2019
Q1 		$25.2M Buy
+136,907
New +$25.3M 4.56% 12

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Chiron Investment Management's VRTX Position: Q1 2024 in Review

Chiron Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 14,496 shares — an estimated $5.9M sold.

Chiron Investment Management first reported a position in VRTX in Q1 2019 and held it in 11 quarters. The position peaked at $25.2M in Q1 2019. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Chiron Investment Management reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Chiron Investment Management sold 14,496 Vertex Pharmaceuticals shares in Q1 2024, an estimated $5.9M.
  • Chiron Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 11 quarters.
  • Chiron Investment Management's Vertex Pharmaceuticals position peaked at $25.2M in Q1 2019.
  • 1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Chiron Investment Management's 13F filing for Q1 2024, filed 13 May 2024.